Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori

American Journal of the Medical Sciences

Volumn 342, Issue 3, 2011, Pages 177-181

  Hu, Tsung Hui ^a,b   Chuah, Seng Kee ^a   Hsu, Ping I ^c,d   Wu, Deng Chyang ^e   Tai, Wei Chen ^a   Chiu, Yi Chun ^a   Wu, Keng Liang ^a   Kuo, Chung Mou ^a   Hu, Ming Luen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b FOOYIN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Amoxicillin; Esomeprazole; Helicobacter pylori infection; Levofloxacin; Metronidazole; Rescue therapies

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEPTIC ULCER; PROSPECTIVE STUDY; TASTE PERVASION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80052259224     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31821fc2aa     Document Type: Article

References (26)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concept in the management of Helicobacter infection. The Maastricht III Consensus Report. Gut 2007;56:772-81. (Pubitemid 46854190)
2. Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: The HYPER Study. Gut 2007;56: 475-9. (Pubitemid 46580501)
3. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: Duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62. (Pubitemid 351664506)
4. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8. (Pubitemid 47196342)
5. Kuo CH, Wang SS, Hsu WH, et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter 2010;15:265-72.
6. Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin- based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design. Gut 2010;59:572-8.
7. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med 2009;67:96-101.
8. Di Caro S, Franceschi F, Mariani A, et al. Second-line levofloxacinbased triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009;41:480-5.
9. Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: A randomized controlled trial. J Antimicrob Chemother 2009; 63:1017-24.
10. Cheng HC, Chang WL, Chen WY, et al. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007;12:359-63.
11. Wu DC, Hsu PI, Chen A, et al. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest 2006;36: 803-9. (Pubitemid 44569969)
12. Hu CT, Wu CC, Lin CY, et al. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol 2007;22:720-3.
13. Hung KH, Sheu BS, Chang WL, et al. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009; 14:61-5.
14. Wu CJ, Hsu PI, Lo GH, et al. Comparison of cetraxate-based and Pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection. J Chin Med Assoc 2004;67:161-7.
15. Hsu PI, Lai KH, Tseng HH, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001;15:195-201.
16. Yakoob J, Abid S, Jafri W, et al. Comparison of biopsy-based methods for the detection of Helicobacter pylori infection. Br J Biomed Sci 2006;63:159-62. (Pubitemid 46033475)
17. Peng NJ, Lai KH, Liu RS, et al. Clinical significance of oral urease in the diagnosis of H. pylori infection by 13C-urea breath test. Dig Dis Sci 2001;46:1772-8.
18. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole- based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005;37:821-5. (Pubitemid 44356109)
19. Coelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: A pilot study. Aliment Pharmacol Ther 2005;21:783-7. (Pubitemid 40469006)
20. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:421-7. (Pubitemid 43382022)
21. Kim JM, Kim JS, Kim N, et al. Comparison of primary and secondary ntimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006;28:6-13.
22. Hsu PI, Lai KH, Wu CJ, et al. High-dose versus low-dose esomeprazole- based triple therapy for Helicobacter pylori infection Eur J Clin Invest 2007;37:724-30. (Pubitemid 47256175)
23. Marzio L, Coraggio D, Capodicasa S, et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006;11:237-42. (Pubitemid 44051349)
24. Shimizu T, Ochiai H, Asell F, et al. Bioinformatics research on inter-racial difference in drug metabolism. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003;18:48-70.
25. Sheu BS, Kao AW, Cheng HC, et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005;21:283-8.
26. Madan A, Holland S, Humbert JE, et al. Racial differences in birth weight of term infants in a northern California population. J Perinatol 2002;22:230-5. (Pubitemid 34461102)